The efficacy of oxytocin gel in postmenopausal women with vaginal atrophy: an updated systematic review and meta-analysis

Table 2 Baseline characteristics for population of the included studies

First author (year)	Group	Sample size	Age (years) Mean (SD)	BMI (kg/m²) mean (SD)	Years after menopause mean (SD)
Jonasson et al. (2011) [14]	Oxytocin	10	59.7	27.2	11.2
Jonasson et al. (2011) [14]	Placebo	10	60.4	26	7.4
Al-saqi et al. (2015) [18]	Oxytocin	24	61.1 (5.3)	23.6 (3.2)	NA
Al-saqi et al. (2015) [18]	Placebo	16	63.2 (5.8)	24.2 (2.6)	NA
Al-saqi et al. (2015)b [18]	Oxytocin	24	62 (5.7)	23.1 (2.4)	NA
Al-saqi et al. (2015)b [18]	Placebo	16	63.2 (5.8)	24.2 (2.6)	NA
Al-Saqi et al. (2016) [19]	Oxytocin	33	63 (5.4)	24.7 (1.7)	NA
Al-Saqi et al. (2016) [19]	Placebo	35	61.3 (7)	23.3 (2.5)	NA
Torky et al. (2018) [15]	Oxytocin	70	54.1 (4.46)	33.45 (4.08)	3.56 (2.11)
Torky et al. (2018) [15]	Placebo	70	54.58 (3.41)	33.4 (4.44)	3.2 (1.51)
Abedi et al. (2020) [17]	Oxytocin	44	54.18 (3.31)	28.5 (1.54)	NA
Abedi et al. (2020) [17]	Placebo	42	54.1 (3.68)	28.8 (1.49)	NA
Jonasson et al. (2020) [16]	Oxytocin	79	58 (3.9)	25.3 (3.5)	NA
Jonasson et al. (2020) [16]	Placebo	78	58.7 (3.1)	25.3 (3.1)	NA
Zohrabi et al. (2020) [28]	Oxytocin	44	54.18 (3.31)	28.5 (1.54)	4.13 (2.01)
Zohrabi et al. (2020) [28]	Placebo	42	54.1 (3.68)	28.8 (1.49)	3.78 (2.33)

ISSN: 1472-6874